Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Approvals In Brief

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Pfizer's Chantix for smoking cessation: Labeling for Pfizer's newly approved selective nicotinic acetylcholine receptor partial agonist Chantix (varenicline) for smoking cessation includes superiority claims over GlaxoSmithKline's Zyban (bupropion). In one study, 44% of Chantix patients were abstinent in treatment weeks nine through 12 compared to 30% of Zyban patients and 17% on placebo, labeling says. Additionally, 29% of Chantix patients were continuously abstinent through the end of treatment compared to 23% of Zyban patients. On May 10, Chantix (formerly Champix) became the first nicotine agonist approved by FDA and the first new prescription medication approved for smoking cessation in nearly a decade. Roll-out of the tablet therapy is slated for the second half of the year...

You may also be interested in...



Pfizer anti-smoking agent EU approval

European authorities approve Pfizer's novel smoking agent varenicline Sept. 26 under the trade name Champix. Varenicline was approved in the U.S. May 10 under the trade name Chantix (1Pharmaceutical Approvals Monthly May 2006, p. 5). Pfizer had sought to use the Champix name in the U.S. as well, but FDA review documents said the name was "overly fanciful and overstates the efficacy of the product" (2Pharmaceutical Approvals Monthly July 2006, p. 27)...

MGI Submits Saforis NDA: Pipeline To Propel Sales To $1 Bil. By 2010 – Firm

MGI Pharma’s recently submitted oral mucositis therapy Saforis and newly approved myelodysplastic syndromes agent Dacogen top a "deep and maturing pipeline" projected to drive corporate sales to $1 bil. by 2010, according the company.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

Topics

UsernamePublicRestriction

Register

LL1135495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel